Expand all sections

Binimetinib

Balimek

Extended indication Treatment of unresectable or metastatic melanoma with an NRAS Q61 mutation.
Therapeutic value No judgement
Registration phase Withdrawn

Product

Active substance Binimetinib
Domain Oncology and Hematology
Main indication Skin cancer
Extended indication Treatment of unresectable or metastatic melanoma with an NRAS Q61 mutation.
Proprietary name Balimek
Manufacturer Pierre Fabre

Registration

Particularity New medicine
Registration phase Withdrawn
Additional remarks Registratieaanvraag teruggetrokken in januari 2018

Therapeutic value

Therapeutic value No judgement

Expected patient volume per year

There is currently nothing known about the expected patient volume.

Expected cost per patient per year

There is currently nothing known about the expected cost.

Potential total cost per year

There is currently nothing known about the possible total cost.

Off label use

There is currently nothing known about off label use.

Indication extension

There is currently nothing known about indication extensions.

Other information

There is currently no futher information available.